Astragalus On Immune Function In Tumor-bearing Mice After Chemotherapy

ObjectiveConstructing T-cell lymphoma model in mice of this study,application of Astragalus (Astragalus mongholicus) in combination with gemcitabine (Gemcitabine) in the treatment of mouse T-cell lymphoma, exploring Astragalus to tumor-bearing mice after chemotherapy of Thl (T helper cell type1cells cellular subpopulations, Thl)/Th2(T helper cell type2cells cellular subpopulations, Th1) type cytokine expression and immune mechanisms to evaluate the protective effect of astragalus on the body’s immune. For immunotherapy of T-cell lymphoma research provides the experimental basis and theoretical basis.Methods1This study was designed to construct animal model of mouse T cell lymphoma.2120C57BL/6mice were randomly divided into5groups, including24for normal control group mice were not vaccinated EL-4cells, other four groups of96mice by EL-4cells, stay a tumor-burdened tumors in mice to1cm3long, will be a tumor-burdened mice according to the original coding input SPSS, random sort randomly divided into4groups by the software, the final group:normal control group (n=24) without any treatment; tumor-bearing mice blank control group (n=24) by intraperitoneal injection of physiological saline,80mg/kg rat weight,1,8,15day administration, three weeks of a cycle; gemcitabine chemotherapy group (n=24) by intraperitoneal injection at a dose of80mg/kg rat1,8,15day administration, three weeks into a cycle;astragalus treatment group (n=24) by intraperitoneal injection dose of12g/kg mice three days of the chemotherapy administered daily dosing; gemcitabine+RA treatment group (amifostine and Calcium folinate) group (n=24) gemcitabine Bin intraperitoneal injection dose were80mg/kg rat1,8,15day administration, three week cycle joint, Astragalus intraperitoneal injection dose were the12g/kg mouse chemotherapy administration, daily administration.3Gross observation and histomorphology study:observe each group every day state of mind and activity in mice, the measurement of body weight in mice, vernier calipers measure the longest diameter path L of tumor and the shortest path W, four groups of tumor-bearing mice respectively to d7, d14tumors had tissue specimen, HE staining preparation tumors had tissue biopsies, optics microscope in each experimental group tumors had organization morphological changes in the different time points.4Survival:daily observation and record the deaths of groups of mice,mice survival statistics.5Enzyme-linked immune sorbent assay (enzyme linked immunosorbent assay, ELISA) four groups of tumor-bearing mice respectively in the first d7, d14take right axillary in mice tumor tissue specimens, the solid-phase antigen or antibody and antigen or antibody enzyme mark principle of determination of different time points in each experimental group tumors had woven fabric of Th1/Th2type cytokines expression.Results1The tumor-bearing mice weight gemcitabine administered7and14days, compared with before administration weight gradually increased. The healthy mice group and the blank control group of tumor-bearing mice gemcitabine pairwise comparisons of the the Bin chemotherapy group, astragalus treatment group, gemcitabine+RA treatment group difference was statistically significant (P<0.05). 2Each group a tumor-burdened mice tumor weight and gemcitabine for7days, gemcitabine, astragalus membranaceus group, gemcitabine plus astragalus membranaceus group the average tumor weight of two groups of mice both comparative differences are statistically significant (P<0.05). Gemcitabine for14days, gemcitabine, gemcitabine plus astragalus membranaceus groups each group the average tumor weight of mice a tumor-burdened mice blank control group, astragalus membranaceus group except two comparative differences are statistically significant (P<0.05).3Observed tumor growth in mice in each experimental group and the group of tumor-bearing mice inoculated7days and9days, the difference was not statistically significant (P>0.05);11days of the vaccination, tumor-bearing miceblank control group with gemcitabine gemcitabine chemotherapy group, gemcitabine+astragalus treatment group except astragalus treatment group difference comparison between any two means was statistically significant (P<0.05), gemcitabine chemotherapy group and astragalus treatment group were inoculated difference comparison between any two means have statistical significance (,P<0.05), the astragalus group with gemcitabine+Astragalus pairwise comparisons of the treatment group difference was statistically significant (P<0.05). Inoculation13days, but the tumor-bearing mice blank control group and astragalus treatment group comparison between any two means has no differences significant difference (P>0.05), gemcitabine He Bin chemotherapy group and gemcitabine+astragalus treatment group compare each other was differences without statistical significance (P>0.05).15days of the vaccination group tumor volume over time growth in addition to gemcitabine chemotherapy with gemcitabine+RA treatment group pairwise comparison difference was not statistically significant (P>0.05), comparison between any two means groups were statistically significance (P<0.05).4The various tumor inhibition rate of tumor-bearing mice, gemcitabine gemcitabine group, Astragalus group, gemcitabine+RA group inhibition rate of52.92%,45.61%,72.81%.5HE staining histopathological observation of visible gemcitabine plus astragalus treatment group have more tumor necrosis area. 6Determination of enzyme-linked immune adsorbent, d7, each tumor-burdened group mice groups cytokines IFN-gamma, the expression of IL-12is on the decline, the Th2type cytokines IL-4, astragalus membranaceus group and gemcitabine chemotherapy plus astragalus treated group is lower than other three groups, astragalus membranaceus group of cytokine i1-10is lower than the normal control group. D14, each a tumor-burdened group mice group treated with astragalus membranaceus and gemcitabine plus astragalus treatment group cytokines IL-12, IFN-gamma expression increased significantly, with gemcitabine plus astragalus treatment group cytokines IL-12, IFN-gamma expression is higher than the astragalus membranaceus group, the Th2cytokine IL-4, IL-10, in the group treated with astragalus membranaceus and gemcitabine+expression of astragalus treatment group decreased obviously, and gemcitabine plus astragalus treatment group of IL-4, and the expression of IL-10below the astragalus treated group, and comparing two groups of cytokine expression comparison and are statistically significant.Conclusions:1Successfully constructed a mouse model of T-cell lymphoma, the tumor volume inhibition rate of tumor HE (hematoxylin Seiichi eosin) staining pathomorphological, Thl/Th2factor changes Confirmed that astragalus joint on T cell lymphoma effective organism immune protective effects in mice.2Astragalus can enhance the immune function of mice, improve the symptoms of disease, prolong the survival period of mice eventually.